TrianglePUBLICATIONS · 38936379
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Oncol
- Publication date
- 2024 Jul
- First author
- Corbacioglu S
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Corbacioglu S
- type
- Author
- name
- Lode H
- type
- Author
- name
- Ellinger S
- type
- Author
- name
- Zeman F
- type
- Author
- name
- Suttorp M
- type
- Author
- name
- Escherich G
- type
- Author
- name
- Bochennek K
- type
- Author
- name
- Gruhn B
- type
- Author
- name
- Lang P
- type
- Author
- name
- Rohde M
- type
- Author
- name
- Debatin KM
- type
- Author
- name
- Steinbach D
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Corbacioglu S
- type
- Author
- name
- Lode H
- type
- Author
- name
- Ellinger S
- type
- Author
- name
- Zeman F
- type
- Author
- name
- Suttorp M
- type
- Author
- name
- Escherich G
- type
- Author
- name
- Bochennek K
- type
- Author
- name
- Gruhn B
- type
- Author
- name
- Lang P
- type
- Author
- name
- Rohde M
- type
- Author
- name
- Debatin KM
- type
- Author
- name
- Steinbach D
- type
- Author
- bibliography ids
- nci-bib-d99e57934b50c2a865c87d6c
- book metadata
- content sha256
- 3e03e5eb6a28706617aac55d32ee1561beffc4b219632e9c3b709ae3c30da7c2
- document type
- citation
- dois
- 10.1016/S1470-2045(24)00202-X
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:38936379
- immutable id
- pubmed:38936379@3e03e5eb6a28706617aac55d32ee1561beffc4b219632e9c3b709ae3c30da7c2
- journal
- abbreviation
- Lancet Oncol
- issn electronic
- 1474-5488
- issn print
- 1470-2045
- issue
- 7
- name
- The Lancet. Oncology
- nlm unique id
- 100957246
- pages
- 922-932
- volume
- 25
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 38936379
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- 4eec83632d0f9431561a4f11128d896a8d025a46d028f7dc0d25e0c08953c9b3
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Jul
- precision
- month
- year
- 2024
- publication types
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Clinical Trial, Phase II
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
Preserved source evidence · Not medical advice